Vanda's NEREUS Outperforms in GLP-1 Vomiting Study
A Surprising Breakthrough in Vomiting Prevention You don't need to be an old hand on Wall Street to see that when a biotech company rolls out positive trial results, ears perk up. Today, Vanda Pharmaceuticals' announcement that their NEREUS™ (tradipitant) drug aced Study 3601 is catching more eyes than initially expected. It's not just about hitting numbers; it's about...
Continue Reading
Important posts: